[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355350-105":59,"doc-detail-355350-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","interventional-clinical-trials-in-metastatic-pulmonary-large-cell-neuroendocrine-carcinoma-a-systematic-review-of-prospective-interventional-trials","Interventional Clinical Trials in Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma - A Systematic Review of Prospective, Interventional Trials","","Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare, aggressive neuroendocrine malignancy, and the best first-line treatment for advanced or metastatic disease is uncertain. A systematic review evaluated prospective interventional clinical trials to define therapeutic evidence and evidence gaps. Out of 2139 records, only four prospective non-randomized studies met inclusion, preventing reliable meta-analysis due to bias and variability. Most trials tested first-line platinum chemotherapy, while immunotherapy was assessed in a single study. Outcomes were modest, with median PFS typically under 6 months and median OS rarely above one year.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/interventional-clinical-trials-in-metastatic-pulmonary-large-cell-neuroendocrine-carcinoma-a-systematic-review-of-prospective-interventional-trials/355350/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/interventional-clinical-trials-in-metastatic-pulmonary-large-cell-neuroendocrine-carcinoma-a-systematic-review-of-prospective-interventional-trials/355350.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the systematic review?","Question",{"text":112,"@type":113},"To evaluate prospective therapeutic evidence in patients with advanced or metastatic pulmonary LCNEC, define current evidence, and identify key gaps to guide future research.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many studies met the inclusion criteria, and why was meta-analysis not performed?",{"text":117,"@type":113},"Only four prospective non-randomized studies were eligible. Due to risk of bias and substantial methodological variability, a meta-analysis could not be reliably performed.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatments were studied most often in the included trials?",{"text":121,"@type":113},"Three trials investigated first-line platinum-based chemotherapy regimens, while only one study evaluated immunotherapy in lung LCNEC.",{"name":123,"@type":110,"acceptedAnswer":124},"What do the review findings suggest about expected clinical outcomes?",{"text":125,"@type":113},"Clinical outcomes were modest, with progression-free survival typically shorter than six months and overall survival rarely exceeding one year.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},355350,1790583614,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Systematic Review  \nInterventional Clinical Trials in Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma: A Systematic Review of Prospective, Interventional Trials  \nElettra Merola 1, *, Maria Pina Dore 1,2 and Giuseppe Fanciulli 1,3  \nAcademic Editor: Naoto T. Ueno and David R. Gandara  \nReceived: 18 February 2026  \nRevised: 9 March 2026  \nAccepted: 12 March 2026  \nPublished: 17 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy;  \n[mpdore@uniss.it](mpdore@uniss.it) (M.P.D.); [gfanciu@uniss.it](gfanciu@uniss.it) (G.F.)  \n2 Department of Medicine, Baylor College of Medicine, One Baylor Plaza Blvd, Houston, TX 77030, USA  \n3 Unit of Endocrinology, AOU Sassari, Viale San Pietro 43b, 07100 Sassari, Italy  \n* Correspondence: [emerola@uniss.it](emerola@uniss.it)  \nSimple Summary  \nLarge cell neuroendocrine carcinoma (LCNEC) of the lung is a rare and aggressive form of lung cancer, accounting for approximately 3% of cases. Despite its clinical relevance, the optimal treatment strategy for advanced or metastatic LCNEC remains unclear. We conducted a systematic review of prospective interventional clinical trials to evaluate the available therapeutic evidence. Only four non-randomized studies met inclusion criteria. Most trials investigated platinum-based chemotherapy in the first-line setting, while immunotherapy was evaluated in only one study. Clinical outcomes were modest, with progression-free survival typically shorter than six months and overall survival rarely exceeding one year. The limited number of trials, small sample sizes, and methodological variability highlight a significant evidence gap. These findings emphasize the urgent need for international collaboration, innovative clinical trial designs, and integration of molecular profiling to improve treatment strategies and enable personalized care for patients with lung LCNEC.  \nAbstract  \nBackground/Objectives: Pulmonary neuroendocrine neoplasms comprise a heterogeneous group of epithelial lung tumors characterized by varying degrees of differentiation and biological aggressiveness. Among high-grade types, large cell neuroendocrine carcinoma (LCNEC) is an uncommon but clinically significant entity, representing approximately 3% of lung cancers, with the optimal first-line therapeutic approach remaining uncertain. Our aim was to evaluate the available prospective therapeutic evidence in patients with advanced or metastatic pulmonary LCNEC, defining the current evidence and identifying key gaps to inform future research. Methods: A systematic literature search was conducted using PubMed, Scopus, and Web of Science (last update: 9 August 2025) . Endpoints included the evaluation of clinical outcomes from interventional trials and safety. Results: Overall, 2139 records were identified through the database search and handsearching. After removal of duplicates and non-eligible records, only 4 prospective, non-randomized studies were eligible for the systematic review. Due to the risk of bias and substantial methodological variability, a meta-analysis could not be reliably performed. Three trials investigated first-line platinum-based chemotherapy regimens, while only one study evaluated immunotherapy in lung LCNEC. Overall clinical outcomes were modest, with benefits appearing limited in duration, with median PFS consistently \u003C6 months and median OS rarely exceeding one year. Conclusions: The findings of this review underscore a persistent  \nand substantial evidence gap in the management of advanced pulmonary LCNEC. Closing this gap will require coordinated international collaborations and innovative trial designs, including molecular analysis as a driver for patient management. Without such efforts, the prospect of ","cbCaipBJ2sBPmqDK","https://ap.wps.com/l/cbCaipBJ2sBPmqDK","pdf",2459411,12,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What was the purpose of the systematic review?\",\"answer\":\"To evaluate prospective therapeutic evidence in patients with advanced or metastatic pulmonary LCNEC, define current evidence, and identify key gaps to guide future research.\"},{\"question\":\"How many studies met the inclusion criteria, and why was meta-analysis not performed?\",\"answer\":\"Only four prospective non-randomized studies were eligible. Due to risk of bias and substantial methodological variability, a meta-analysis could not be reliably performed.\"},{\"question\":\"What treatments were studied most often in the included trials?\",\"answer\":\"Three trials investigated first-line platinum-based chemotherapy regimens, while only one study evaluated immunotherapy in lung LCNEC.\"},{\"question\":\"What do the review findings suggest about expected clinical outcomes?\",\"answer\":\"Clinical outcomes were modest, with progression-free survival typically shorter than six months and overall survival rarely exceeding one year.\"}]","Interventional Clinical Trials in Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma - A Systematic Review of Prospective, Interventional Trials | PDF",1790117988,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dcbbcc8935c4263da7a2affa37eb2070.webp",983,1390,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dd1c9a8578c745e8866d7f58c435504.webp",982,1388,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62c45e81eec37a8fa6e76d154a39c2f7.webp",981,1387,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d232287f0cc425bce61ccd7e0b2046d.webp",980,1385]